今日特讯！小米维权再出击！起诉蹭名企业不正当竞争

小米维权再出击！起诉蹭名企业不正当竞争

北京 - 2024年6月16日，据悉，小米科技有限责任公司（以下简称“小米”）近日对青岛小米汽车销售服务有限公司（以下简称“青岛小米汽车”）提起不正当竞争纠纷诉讼，该案将于6月14日在青岛市黄岛区人民法院开庭审理。

此次诉讼是小米在维护自身品牌权益方面采取的又一次重要举措。天眼查信息显示，青岛小米汽车成立于2016年7月，注册资本100万人民币，由两位自然人共同持股，其与小米相关公司并无任何股权关联。该公司主要经营范围包括汽车销售、汽车维修、汽车零部件零售等。

小米方面表示，青岛小米汽车在经营活动中使用了与小米商标、品牌名称高度相似的名称、标识等，并在其官方网站、宣传资料以及线下实体店等多个渠道进行推广宣传，容易使消费者产生混淆，误认为其与小米存在关联，从而侵害了小米的合法权益。

近年来，小米在智能手机、智能家居、物联网等领域取得了长足的进步，品牌知名度和影响力不断提升。然而，也正因如此，一些不法企业试图蹭小米的热度，通过傍名、抄袭等方式进行不正当竞争，获取不当利益。

小米表示，将坚决依法打击一切侵权行为，维护自身合法权益，并呼吁相关部门加强对市场秩序的监管，共同营造公平竞争的市场环境。

以下是对新闻稿的几点补充：

• 除了青岛小米汽车之外，小米还曾起诉过其他多家蹭名企业，包括“小米汽车服务公司”、“小米之家服务中心”等。
• 小米在知识产权保护方面一直采取积极措施，此前曾多次获得相关荣誉，例如2021年被评为“中国知识产权示范企业”。
• 本次诉讼也引发了业界对品牌保护和市场秩序的广泛关注。有专家表示，蹭名行为不仅侵害了被蹭品牌的合法权益，也扰乱了市场秩序，消费者应谨慎识别，避免上当受骗。

新的标题：

• 小米再战碰瓷！起诉青岛小米汽车销售服务有限公司不正当竞争
• 维护品牌权益不容侵犯！小米起诉青岛小米汽车公司蹭名
• 打击蹭名行为，守护市场秩序！小米维权再出击

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.